Shares of Lupin Ltd were trading in the green and 1% higher on 9 January despite the company’s Pithampur unit-1 manufacturing facility has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) 

The company’s Pithampur Unit-1 manufacturing facility generates both APIs and finished goods.

The EIR was assigned the inspection grade of Voluntary Action Indicated (VAI) during a facility inspection that took place between 16 September and 27 September 2024.

On 30 December, the pharmaceutical behemoth acquired the Indian Huminsulin brand from Eli Lilly in order to broaden its diabetes product line.

The Huminsulin series helps adults and children better control their blood sugar levels and is used to treat type 1 and type 2 diabetes mellitus.

At 11:47 am, the shares of Lupin were trading 1.77% higher at Rs 2,291.95 on NSE.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!